2003-09--2006-06 Master's: Ocean University of China
1999-09--2003-06 Bachelor's: Ocean University of China
2015-10~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher
2011-10~2015-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher
2009-07~2011-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Assistant Researcher
China Patent Silver Award (2023): Second Prize, National Level
Shanghai Workers' Excellent Innovation Achievement Award (2019): Second Prize, Other
Shanghai Pharmaceutical Science and Technology Award (2017): First Prize, Municipal Level
Sanofi-Shanghai Institute of Biological Sciences Outstanding Young Talent Award (2014): Institute Level
Shanghai Institute of Materia Medica 'Outstanding Young Scientific Worker' (2014): Institute Level
Chinese Pharmacological Society Servier Young Pharmacologist Award (2012): Other
Research
Tumor Pharmacology Tumor Biology
Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors, JOURNAL OF MEDICINAL CHEMISTRY, 2023
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer, Signal Transduction and Targeted Therapy, 2023
Discovery of 10H-Benzobpyrido2,3-e1,4oxazine AXL Inhibitors via Structure-Based Drug Design Targeting c-Met Kinase, JOURNAL OF MEDICINAL CHEMISTRY, 2022
Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors, JOURNAL OF MEDICINAL CHEMISTRY, 2022
F-18-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis, THERANOSTICS, 2022
Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor, JOURNAL OF MEDICINAL CHEMISTRY, 2021
Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage, JOURNAL OF MEDICINAL CHEMISTRY, 2021
Design, synthesis and biological evaluation of pyrazolo3,4-dpyridazinone derivatives as covalent FGFR inhibitors, ACTA PHARMACEUTICA SINICA B, 2021
The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation, MOLECULAR CANCER THERAPEUTICS, 2021
Discovery of pyrrolo2,3-dpyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021
Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models., CANCER IMMUNOLOGY RESEARCH, 2020
Discovery and Development of a Series of Pyrazolo3,4-dpyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design, JOURNAL OF MEDICINAL CHEMISTRY, 2019
The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors, MOLECULAR CANCER THERAPEUTICS, 2019
Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo2,3-bpyrazine scaffold: structure-activity relationship, crystal structural characterization and and in vivo study, ACTA PHARMACEUTICA SINICA B, 2019
Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019
Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1H-benzo d azepin-7-yl)amino)pyrazine core, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019
Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes (FXRPD)-P-high-L1(low) NSCLC to Anti-PD-1 Immunotherapy, CANCER IMMUNOLOGY RESEARCH, 2019
Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019
Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019
Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and in Vivo Antitumor Profiles, CHEMICAL RESEARCH IN TOXICOLOGY, 2018
Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors (vol 61, pg 9085, 2018), JOURNAL OF MEDICINAL CHEMISTRY, 2018
Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018
Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018
Structure-Based Discovery of a Series of 5H-Pyrrolo2,3-bpyrazine FGFR Kinase Inhibitors, MOLECULES, 2018
Structure-Based Discovery of a Series of 5H-Pyrrolo2,3-bpyrazine FGFR Kinase Inhibitors, MOLECULES, 2018
Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models, MOLECULAR CANCER THERAPEUTICS, 2018
Discovery and Biological Evaluation of a Series of Pyrrolo2,3- b pyrazines as Novel FGFR Inhibitors, MOLECULES : A JOURNAL OF SYNTHETIC CHEMISTRY AND NATURAL PRODUCT CHEMISTRY, 2017
Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer., ACTA PHARMACOLOGICA SINICA, 2017
Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer, JOURNAL OF MEDICINAL CHEMISTRY, 2017
Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017
Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer, 中国药理学报：英文版, 2017
Palladium-Catalyzed, Silver-Assisted Direct C-5-H Arylation of 3-Substituted 1,2,4-Oxadiazoles under Microwave Irradiation, ADVANCED SYNTHESIS & CATALYSIS, 2017
Synthesis and structure���activity relationship study of pyrazolo3,4-dpyrimidines as tyrosine kinase RET inhibitors, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017
c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors, CLINICAL CANCER RESEARCH, 2017
Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017
Cyanobacterial peptides as a prototype for the design of cathepsin D inhibitors, JOURNAL OF PEPTIDE SCIENCE, 2017
Discovery and Biological Evaluation of a Series of Pyrrolo2,3-bpyrazines as Novel
Area of Focus
3D Genomics | Epigenetics | Transcriptional Regulation | Cardiovascular Diseases | Cancer | Human Diseases | Molecular Biology | Cellular Medicine | Genetic Analysis | Disease Mechanisms
